Anti-Human CD20 (Rituximab) [Clone 10F381] – APC

Anti-Human CD20 (Rituximab) [Clone 10F381] – APC

Product No.: LT903

- -
- -
Product No.LT903
Clone
10F381
Target
CD20
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
B1; S7; Bp35; CVID5; MS4A2; LEU-16; MS4A1; membrane spanning 4-domains A1
Isotype
Human IgG1κ
Applications
FC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Cynomolgus Monkey
Rhesus Monkey
Human
Host Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Immunogen
Human lymphoblastoid cell line SB.
Product Concentration
0.2 mg/ml
Formulation
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
Next Day 2-8°C
Excitation Laser
Red Laser (650 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Rituximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Rituximab. Clone 10F381 recognizes human CD20. This product is for research use only.
Background
CD20 is a 33-37 kD transmembrane-spanning phosphoprotein found on the surface of developing B-cells and various B-cell malignancies. CD20 is a popular target for mAb therapy because depleting developing B-cells generally does not cause permanent side effects (due to the fact that mature plasma cells and B-cell progenitors do not express CD20 and that there is limited expression of CD20 among other cell lineages). Rituximab is a chimeric monoclonal antibody that binds to CD20. The precise function of CD20 is still unknown. However, it is suspected to play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration, and allowing the activation of B cells. Rituximab is used to treat some autoimmune diseases and types of cancer such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis among others. The Fc portion of Rituximab mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Rituximab increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen) and also induces apoptosis of CD20+ cells. This ultimately results in the elimination of B cells (including the cancerous ones) from the body, and thus allows a new population of healthy B cells to develop from lymphoid stem cells. Anti-Human CD20 (Rituximab) utilizes the same variable regions from the therapeutic antibody Rituximab making it ideal for research projects.
Antigen Distribution
CD20 is primarily found on the surface of immune system B cells. CD20 is highly expressed in the lymph node, and to a lesser extent, the spleen and appendix.
PubMed
NCBI Gene Bank ID
Research Area
Biosimilars
.
Costimulatory Molecules
.
Immunology

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Using Research-Grade Rituximab Biosimilars in PK Bridging ELISA

Rituximab biosimilars, which are structurally and functionally similar to the reference medicinal product Rituximab (Rituxan or Mabthera), play a critical role as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISA assays. These assays are designed to measure the concentration of Rituximab in serum samples, providing valuable data for pharmacokinetic studies.

Calibration and Principle

  1. Calibration with Biosimilars: Research-grade Rituximab biosimilars are used to establish a standard curve in PK bridging ELISA assays. These biosimilars are calibrated against internationally recognized standards, ensuring that the concentrations measured are accurate and reliable. Calibration involves preparing a series of known concentrations of the biosimilar, which are then used to determine the concentrations of Rituximab in serum samples.

  2. ELISA Principle: The ELISA assay typically involves a sandwich format where the plate is coated with a capture antibody specific to Rituximab. The sample containing Rituximab is then incubated, followed by the addition of a detection antibody conjugated to an enzyme. The enzyme activity is directly proportional to the amount of Rituximab present in the sample.

Role in PK Bridging Studies

  1. PK Bridging Studies: PK bridging studies are essential for demonstrating bioequivalence between a biosimilar and its reference drug. In these studies, ELISA assays are used to compare the pharmacokinetic profiles of the biosimilar and the reference drug, ensuring that they behave similarly in the body.

  2. Ensuring Equivalence: By using biosimilars as calibration standards, researchers can ensure that the ELISA assay accurately measures the drug concentration in serum samples. This is critical for demonstrating the equivalence of the biosimilar to the reference product in terms of pharmacokinetics.

In summary, research-grade Rituximab biosimilars are used as calibration standards in PK bridging ELISA assays to ensure accurate measurement of Rituximab concentrations in serum samples. This accuracy is crucial for pharmacokinetic studies, which are essential for establishing the bioequivalence of biosimilars to their reference drugs.

Standard flow cytometry protocols involving a conjugated Rituximab biosimilar (e.g., PE or APC-labeled) are used to directly assess CD20 expression and the binding capacity of therapeutic anti-CD20 antibodies on B cells, in research and quality control settings.

The established procedural workflow typically includes:

  • Sample Preparation: Use fresh or properly preserved blood or PBMCs (Peripheral Blood Mononuclear Cells). Common anticoagulants are EDTA, sodium heparin, or specialized tubes with preservative reagents that maintain antigen stability up to 14 days from collection.

  • Antibody Staining:

    • Incubate cells with the conjugated Rituximab biosimilar, such as PE- or APC-labeled Rituximab, at an optimized concentration (determined by titration) for 20–30 minutes at 4°C or room temperature in the dark.
    • Optionally, stain with additional markers (e.g., CD19 APC-conjugated) to identify B-cell populations.
  • Washing: Wash cells in PBS or other appropriate buffer to remove unbound antibody.

  • Data Acquisition:

    • Collect data on a flow cytometer set for the fluorochrome used (e.g., PE, APC channels).
    • Gate on lymphocytes via scatter properties and select B cells (CD19+) for analysis of CD20 expression.
  • Controls:

    • Include unstained controls, isotype controls, and compensation controls.
    • Use untreated or known positive/negative samples for reference and assay validation.
  • Assay Validation (for QC or potency testing):

    • Assess robustness, specificity, precision (repeatability/intermediate precision), and freedom from interference as per regulatory guidelines (e.g., ICH, CLSI H62).
    • Confirm the ability to discriminate between CD20-positive and -negative cells, and quantify the degree of antibody binding.
  • Analysis:

    • Quantify mean fluorescence intensity (MFI) or percent positive cells to determine CD20 expression or Rituximab binding.
    • Compare between test biosimilar and reference products for lot-to-lot quality control or activity assessment.

Key protocol notes and considerations:

  • Direct conjugated Rituximab biosimilars allow for measurement of the target directly, confirming specific binding to native CD20 on living cells—important for preclinical screening or post-treatment monitoring.
  • Preserved samples may introduce artifacts via epitope masking or impact tandem dye performance; rigorous validation of modified protocols is recommended for reliable results.
  • After Rituximab treatment, CD20 may be undetectable by flow cytometry on B cells due to antigen modulation or internalization, so timing and controls are critical in post-treatment evaluation.

Typical usage scenarios include:

  • Characterizing binding capacity of Rituximab biosimilars to CD20 for biosimilar QC.
  • Enumerating CD20+ B cells in patient blood, especially in monitoring post-therapy depletion.
  • Assay validation and potency testing for regulatory submission and product release.

The protocols may differ slightly between research, clinical, and manufacturing environments, but the outlined approach remains consistent.

Biopharma companies use a comprehensive set of analytical assays to confirm the structural and functional similarity of a proposed biosimilar to its originator (reference) drug. These assays target both structural attributes (such as amino acid sequence and folding) and functional activities (such as target binding and biological efficacy), with results forming the core evidence required by regulatory bodies for biosimilar approval.

Key Analytical Assays and Their Purposes

  • Primary Structure Analysis
    • Peptide mapping by LC-MS is used to verify the exact amino acid sequence and confirm identity.
  • Post-Translational Modification Detection
    • Assays like HPAEC-PAD and LC-MS identify differences in glycosylation and other modifications that affect function/immunogenicity.
  • Higher-Order Structure Characterization
    • Techniques such as circular dichroism (CD), Fourier-transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), and nuclear magnetic resonance (NMR) confirm correct folding and 3D structure.
  • Purity and Impurity Profile
    • Size-exclusion chromatography (SEC-HPLC), ion-exchange chromatography (IEX-HPLC), and analytical ultracentrifugation (AUC-SV) measure aggregates, fragments, or charge variants, ensuring safety and product consistency.
  • Functional and Biological Activity
    • ELISA, surface plasmon resonance (SPR), and cell-based potency assays confirm that both the mechanism of action and the biological activity (such as target binding or effector function) match those of the originator drug.
  • Statistical Analysis
    • All results are compared using statistical methods to quantitatively show high similarity, ensuring that any minor differences are not clinically meaningful.

Where the Leinco Biosimilar Is UsedLeinco is known as a supplier of research-grade biosimilar antibodies and related reagents. In structural and functional similarity studies, Leinco biosimilar proteins may be used as:

  • Comparators to validate or calibrate analytical methods.
  • Reference materials in assay development (e.g., as positive controls in ELISA, SPR, or cell-based assays).
  • Testing standards to ensure assay sensitivity and specificity or to benchmark assay performance.

However, for regulatory approval of a clinical biosimilar, direct comparison must ultimately use the FDA- or EMA-licensed originator product, not a commercial research biosimilar. Leinco’s biosimilars are mainly intended for research purposes, method development, or as secondary standards, rather than as the principal comparator in regulatory filings.

Summary Table of Analytical Assays for Biosimilarity

Analytical CategoryExample TechniquesPurpose
Primary StructureLC-MS, Peptide MappingSequence verification
Post-Translational ModificationsLC-MS, HPAEC-PADGlycosylation, deamidation, etc.
Higher-Order StructureCD, NMR, FTIR, DSCFolding, conformation
Purity & ImpuritiesSEC-HPLC, IEX-HPLC, AUCAggregates, fragments, charge variants
Biological FunctionELISA, SPR, Cell AssaysTarget binding, potency, mechanism of action

This comprehensive analytic and functional testing provides the totality of evidence required to demonstrate biosimilarity, with close head-to-head comparison to the reference product at every stage.

References & Citations

1. Mato, A. et al. (2018) Oncologist. 23(3):288-296.
2. Richards, K. et al. (2018) Front Oncol. 8: 163.
Flow Cytometry

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.